Abstract
Objective: Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss.
Design: Human studies using liraglutide 3.0 mg daily dose were selected through search based on PubMed listings and the Clinical trials.gov database using the term “liraglutide”.
Results: During 56 weeks of treatment, liraglutide 3.0 mg treatment resulted in 5.9-8.0% weight reduction, while the placebo-subtracted weight loss was 3.9-6.0%. The proportion of treated patients with ≥ 5% weight loss was 50-76%, while the placebo-subtracted proportion was 29-46%. Liraglutide 3.0 mg treatment also induced a decrease in waist circumference, serum triglycerides, insulin resistance, blood pressure and an increase in high density lipoprotein-cholesterol (HDL-C). The most common side effects were nausea, hypoglycemia, diarrhea, constipation, vomiting and headache. In the majority of patients liraglutide 3.0 mg was well tolerated.
Conclusion: Liraglutide 3.0 mg appears to be an effective adjunct to a comprehensive lifestyle intervention to achieve weight reduction and treat obesity-related comorbidities.
Keywords: Liraglutide, glucagon-like peptide-1 agonist, weight loss, lipids, blood pressure, side effects.
Current Vascular Pharmacology
Title:The Current Role of Liraglutide in the Pharmacotherapy of Obesity
Volume: 14 Issue: 2
Author(s): Georgios A. Christou, Niki Katsiki and Dimitrios N. Kiortsis
Affiliation:
Keywords: Liraglutide, glucagon-like peptide-1 agonist, weight loss, lipids, blood pressure, side effects.
Abstract: Objective: Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss.
Design: Human studies using liraglutide 3.0 mg daily dose were selected through search based on PubMed listings and the Clinical trials.gov database using the term “liraglutide”.
Results: During 56 weeks of treatment, liraglutide 3.0 mg treatment resulted in 5.9-8.0% weight reduction, while the placebo-subtracted weight loss was 3.9-6.0%. The proportion of treated patients with ≥ 5% weight loss was 50-76%, while the placebo-subtracted proportion was 29-46%. Liraglutide 3.0 mg treatment also induced a decrease in waist circumference, serum triglycerides, insulin resistance, blood pressure and an increase in high density lipoprotein-cholesterol (HDL-C). The most common side effects were nausea, hypoglycemia, diarrhea, constipation, vomiting and headache. In the majority of patients liraglutide 3.0 mg was well tolerated.
Conclusion: Liraglutide 3.0 mg appears to be an effective adjunct to a comprehensive lifestyle intervention to achieve weight reduction and treat obesity-related comorbidities.
Export Options
About this article
Cite this article as:
Christou A. Georgios, Katsiki Niki and Kiortsis N. Dimitrios, The Current Role of Liraglutide in the Pharmacotherapy of Obesity, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161113666150615111951
DOI https://dx.doi.org/10.2174/1570161113666150615111951 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Cardiology Reviews Oxidative Stress: The Old Enemy in Alzheimers Disease Pathophysiology
Current Alzheimer Research Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Contribution of Inflammatory Processes to Nerve Cell Toxicity by Bilirubin and Efficacy of Potential Therapeutic Agents
Current Pharmaceutical Design 5 Hz Repetitive Transcranial Magnetic Stimulation with Maximum Voluntary Muscle Contraction Facilitates Cerebral Cortex Excitability of Normal Subjects
CNS & Neurological Disorders - Drug Targets Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Gender Differences in Hemodynamic Regulation and Cardiovascular Adaptations to Dynamic Exercise
Current Cardiology Reviews Scleroderma Renal Crisis Accompanied by New-Onset Pulmonary Hypertension: An Acute Systemic Endothelial Injury? Case Report and Literature Review
Inflammation & Allergy - Drug Targets (Discontinued) The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis
Current Pharmaceutical Design Diabetes Mellitus and Renal Function: Current Medical Research and Opinion
Current Diabetes Reviews The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure
Current Pharmaceutical Design The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention (Discontinued) The sdLDL Reduces MRC1 Expression Level and Secretion of Histamin e in Differentiated M2-macrophages from Patients with Coronary Artery Stenosis
Cardiovascular & Hematological Disorders-Drug Targets Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Pharmacological Chemistry and Biomedical Implications of Chemical Ingredients from <i>Parthenium hysterophorus</i>
Current Topics in Medicinal Chemistry Cholinergic Treatment of Traumatic Brain Injury
Current Drug Therapy A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions
CNS & Neurological Disorders - Drug Targets Hereditary Haemorrhagic Teleangiectasia: Diagnostic Imaging of Visceral Involvement
Current Pharmaceutical Design Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review
Current Drug Metabolism